RESEARCH-USE BIOSIMILAR ANTIBODY
Crizanlizumab
Monoclonal antibody · IgG2
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
TARGETSELP
YMonoclonal antibody
CATALOGSC-BS-651
CATALOG NUMBERSC-BS-651
MOLECULAR WEIGHTApprox. 146.21 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
Crizanlizumab is a recombinant research-use antibody directed against SELP.